Company Overview and News

4
Royal Gold's Fiscal Fourth Quarter Results Analysis

16h seekingalpha
Royal Gold reported revenues of $116.2 million in the fiscal fourth quarter, up about 6.7% from the $108.9 million reported last year.
WPM SAND SSL NGD SDDXF NGDAF GDX CG SNXZF NGD RGLD CAGDF FNV RGL

3
Sandstorm Gold: Deep Value Opportunity

17h seekingalpha
Sandstorm Gold is a rapidly growing precious metals royalty and streaming company that is trading at discount to its peers.
WPM SAND SSL SLW SDDXF SNXZF SLW

5
Wheaton Precious Metals' Second Quarter Results Analysis

2018-09-18 seekingalpha - 1
Wheaton Precious Metals announced in August adjusted net earnings of $73 million ($67 million in Q2 2017,) or $0.16 a share.
WPM FR PPPMF RGLD SAND SSL SDDXF SNXZF AG PPP P RGL

28
Integra Resources: Huge Potential Flying Well Under The Radar

2018-09-05 seekingalpha
The recent drill results (including 2.16 g/t of gold equivalent over 220.98 meters) confirm the huge exploration potential.
IRRZF SAND SSL ICG SDDXF ABX K SNXZF ICGQF ELD KGC EGO ABX

13
Gold Mining Bull: Top News For August 2018

2018-09-01 seekingalpha
Coeur Mining made a move to buy a heap leach gold deposit in Nevada; Northern Star goes to Alaska for its next mine.
RIO RIO GTBDF KGI.DB NST FCX BFDRF GSV NSU BFD RTPPF MUX.RTWI RTNTF MUX GG KL SAND SSL SDDXF KGI MUX KGI.DB.A CDEUW NULGF SNXZF PSPGF NESRF CDE RIO GBR NHRNY

4
Franco-Nevada: Second-Quarter Results Analysis

2018-08-21 seekingalpha
Despite second-quarter results that were shy of estimates primarily in revenues, it should be wrong to classify this quarter as a miss.
WPM SAND SSL SDDXF OKSWF CTLR GDX SNXZF RGLD OR OSKGF CLR FNV RGL

10
GDX: New High/New Low Ratio Remains Bearish

2018-08-16 seekingalpha - 2
The Gold Miners Index continues to make new lows with minimal reprieve from the selling pressure.
KGI.DB NGDAF GSV NGD AGI MUX.RTWI MAG AMGGF MUX KL ABX SAND SSL NGD SDDXF ABX KGI MUX KGI.DB.A SNXZF AGI GORO HL MAG

4
Erdene Provides Second Quarter Project Review and Financial Results

2018-08-14 globenewswire
HALIFAX, Nova Scotia, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Erdene Resource Development Corp. (TSX:ERD) ("Erdene" or "Company") is pleased to provide an update on second quarter corporate and project activities, along with an outlook for the second half of 2018. This release should be read in conjunction with the Company’s Q2-2018 Financial Statements and MD&A on the Company’s website or on SEDAR.
SAND SSL SDDXF SNXZF TCKRF ERDCF ERD TECK

3
Sandstorm Gold: Cash Flow Machine

2018-08-11 seekingalpha
Operating cash flow, excluding changes in non-cash working capital, was $12.3 million, compared to $11.21 million last quarter.
WPM SAND SSL SDDXF NXS EDVMF SNXZF NXXGD NXXGF EDVVF EVR MRLDF EDV MARL

3
Sandstorm Gold (SAND) Reports Break-Even Earnings for Q2

2018-08-06 zacks
Sandstorm Gold (SAND - Free Report) just reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.
SAND SSL SDDXF SNXZF BGSF

4
Cobalt27: Emerging Name, Currently Available At A Discount

2018-08-06 seekingalpha
Cobalt is an essential ingredient for Lithium-ion batteries. Supply is tight and getting tighter. Gaining meaningful direct exposure to cobalt is near-impossible to achieve.
WPM SAND SSL SDDXF ABX OKSWF SNXZF SLW RGLD HIG RNX RNX.WT CBLLF SLW RNKLF KNTNF OR HLPCF OSKGF SCYYF SCY RGL ABX

12
Sandstorm Gold's (SAND) CEO Nolan Watson on Q1 2018 Results - Earnings Call Transcript

2018-08-02 seekingalpha - 3
Good morning. My name is Leonie, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Sandstorm Gold Limited Second Quarter Results Conference Call. All lines have been placed on mute to prevent any background noise.
ICG RIO RIO YRI MEAOF NXXGD BTR ICGQF RTPPF MUX.RTWI NXXGF AUY EDVVF RTNTF MUX EDV WPM SAND SSL SDDXF MUX NXS EDVMF SNXZF RGLD RIO EVR RGL

38
LULU Stock Price - lululemon athletica inc. Stock Quote (U.S.: Nasdaq) - MarketWatch

2018-07-24 marketwatch - 1
Lululemon Athletica Inc. said late Thursday it has agreed to buy back 3.3 million of its shares in a private transaction with funds affiliated with Advent International Corp. The shares will be repurchased under the company's recently increased $600 million share buyback program, and funded with cash on hand and borrowing, Lululemon said. Advent also has told Lululemon that it has sold an additional 6.
SAND SSL SDDXF UAA 2331 PANW AMD SNXZF SFIX UA NAT UBS LULU VNET MS ULSGF

7
Sandstorm Gold Royalties Provides Corporate and Asset Updates

2018-07-16 accesswire - 1
VANCOUVER, BC / ACCESSWIRE / July 16, 2018 / Sandstorm Gold Ltd. ("Sandstorm Gold Royalties,'' "Sandstorm" or the "Company") (NYSE American: SAND; TSX: SSL) is pleased to provide an update related to share repurchases under the Company's Normal Course Issuer Bid ("NCIB"), recent developments from the Company's royalty portfolio, as well as the acquisition of eight royalties on exploration-staged properties.
YRI KGI.DB MALRY MEAOF AU NXXGD MIN AULGF NXXGF AUY EDVVF AGG KL EDV SSL SAND SDDXF KGI NXS KGI.DB.A EDVMF SNXZF EQXGF EVR MALRF ERDCF

5
Sandstorm Gold: This Is Big News

2018-07-16 seekingalpha - 2
The PFS confirms that Hod Maden is likely to be an economical mine, although there are some risks/uncertainties to be aware of.
SAND SSL SDDXF SNXZF MRLDF MARL

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 00B7YC668